Pulmatrix, Inc. (PULM)

NASDAQ: PULM · IEX Real-Time Price · USD
1.918
+0.028 (1.47%)
At close: Jun 14, 2024, 4:00 PM
1.880
-0.038 (-1.97%)
After-hours: Jun 14, 2024, 7:40 PM EDT
1.47%
Market Cap 7.00M
Revenue (ttm) 11.68M
Net Income (ttm) -8.85M
Shares Out 3.65M
EPS (ttm) -2.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,239
Open 1.900
Previous Close 1.890
Day's Range 1.850 - 1.960
52-Week Range 1.550 - 2.880
Beta 0.94
Analysts Strong Buy
Price Target 10.00 (+421.46%)
Earnings Date Aug 8, 2024

About PULM

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbatio... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 22
Stock Exchange NASDAQ
Ticker Symbol PULM
Full Company Profile

Financial Performance

In 2023, Pulmatrix's revenue was $7.30 million, an increase of 20.21% compared to the previous year's $6.07 million. Losses were -$14.12 million, -25.03% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PULM stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target
$10.0
(421.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other relat...

Other symbols: MNKD
16 days ago - PRNewsWire

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improve...

4 weeks ago - PRNewsWire

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Ph...

5 weeks ago - PRNewsWire

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a signif...

2 months ago - PRNewsWire

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix  P...

5 months ago - PRNewsWire

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 20...

7 months ago - PRNewsWire

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD,...

9 months ago - PRNewsWire

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolli...

10 months ago - PRNewsWire

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3...

11 months ago - PRNewsWire

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to ad...

1 year ago - PRNewsWire

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

LEXINGTON, Mass. , June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and cen...

1 year ago - PRNewsWire

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Pulmatri...

1 year ago - PRNewsWire

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023...

1 year ago - PRNewsWire

Pulmatrix Supports World Asthma Day 2023

LEXINGTON, Mass. , May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc.  (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and cent...

1 year ago - PRNewsWire

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 pro...

1 year ago - PRNewsWire

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc.  (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

1 year ago - PRNewsWire

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

1 year ago - PRNewsWire

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

1 year ago - PRNewsWire

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested LEXINGTON,...

1 year ago - PRNewsWire

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON,...

1 year ago - PRNewsWire

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4 2022 L...

1 year ago - PRNewsWire

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass. , ...

2 years ago - PRNewsWire

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

LEXINGTON, Mass. , July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

2 years ago - PRNewsWire

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceut...

2 years ago - PRNewsWire

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

LEXINGTON, Mass. , March 29, 2022  /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and n...

2 years ago - PRNewsWire